Onconetix (ONCO) Intangibles (2023 - 2024)
Onconetix (ONCO) posted quarterly Intangibles of $21.4 million for Q3 2024, up 19.59% year-over-year from $17.9 million in Q4 2023, and up 5.44% quarter-over-quarter from $20.3 million in Q2 2024.
Onconetix (ONCO) Intangibles (2023 - 2024) Analysis & Trends
Onconetix (ONCO) has reported Intangibles for 2 consecutive years, with $21.4 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Intangibles rose 19.59% year-over-year to $21.4 million; the TTM figure through Sep 2024 stood at $21.4 million (up 19.59% YoY), while the FY2023 annual figure was $25.4 million, changed N/A from the prior year.
- Intangibles grew to $21.4 million in Q3 2024 per ONCO's latest filing, from $20.3 million in the prior quarter.
- Across five years, Intangibles topped out at $25.4 million in Q4 2023 and bottomed at $17.9 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 21.41 Mn |
| Jun 30, 2024 | 20.31 Mn |
| Mar 31, 2024 | 21.68 Mn |
| Dec 31, 2023 | 25.41 Mn |
| Sep 30, 2023 | 17.91 Mn |
| Jun 30, 2023 | 17.91 Mn |